83,000 US Military veteran patients were studied to understand the risks and benefits of Testosterone Therapy for patients diagnosed with low testosterone. The study found that men diagnosed with ‘Low T’ and restored to normal testosterone levels through physician guidance had lower risks of heart attack, lower risks of stroke, and lower risks of death than the men who lived with low testosterone levels. This study indicates that testosterone therapy improves heart health.
This study was published in August, 2016 in the European Heart Journal after reviewing the cases of 83,000 US Veterans, over the age of 50, treated between 1999 and 2014. One of the groups tested showed that Men treated being treated with Testosterone Therapy were 24% less likely to suffer a heart attack, 36% less likely to suffer a stroke and 56% less likely to die during the follow-up period. The studies results seem to advocate for testosterone replacement therapy, however Dr. Barua stresses the need for “appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy. Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in [heart attack] or stroke and had significantly less benefit on mortality.”
Hormone Therapeutics agrees that one clear point in the study is that patients were under physician guidance and their testosterone therapy was only shown to be beneficial when bringing the patients back from low testosterone levels to normal testosterone levels. It’s important to note that this study did not show health benefits from patients who were not brought back to normal levels. This is also not an analysis of men taking high dosages of Testosterone past normal levels and what that does to one’s health. While traditionally, testosterone therapy has not been prescribed with a goal of improving heart health, this study should lead to more studies to look at that possibility.
Click here to read more about this study from the medical community: Science Daily Article
Saleamp Design January 4th, 2016
Tags: benefits of testosterone, cardiovascular, cardiovascular disease, cardiovascular health, cardiovascular risk, health, heart disease, low testosterone levels, myocardial infarction, quality of life, testosterone therapy
The FDA approved a new treatment for women with sexual desire disorder, medically known as Hypo-Active Sexual Desire Disorder (HSDD). The pill, nicknamed the Female Viagra, will only be available through healthcare providers. HSDD is characterized through low sexual preference that reasons marked distress or interpersonal issue and isn’t due to a co-existing medical or psychiatric situation, troubles inside the courting, or the effects of a medication or other drug substance. HSDD is received while it develops in a patient who formerly had no troubles with sexual desire. HSDD is generalized when it occurs irrespective of the sort of sexual hobby, the state of affairs or the sexual accomplice. This female sexual desire treatment had been under scrutiny for many years prior by the FDA due to the number of side effect by its previous male version of the drug; but which is now irrelevant.
Here is the press release by the FDA:
Saleamp Design August 20th, 2015
New studies are coming out showing the benefits of Testosterone Therapy bringing men back to normal testosterone levels are improving life expectancy in men and decreasing their risks for heart attack or stroke. The key finding in this study co-authored by a researchers at the University of Kansas and in India was that the patients testosterone levels were supplemented adequately to reach normal levels.
Learn more about this August 2015 study here:
Saleamp Design August 18th, 2015
Tags: anti-aging, benefits of testosterone, benefits to your body, cardiovascular, cardiovascular disease, cardiovascular health, cardiovascular risk, decreased cardiac risk, decreased heart risk, Hormone Replacement physician, hormone replacement therapy, Improved health, increased longevity, life expectancy, longevity, low testosterone, low testosterone levels, lower cardiovascular risk, lower health risks, myocardial infarction, quality of life, Testosterone replacement therapy, testosterone therapy
“Gross data mismanagement” led to unreliable results that contradicted 30+ years of medical literature, producing a media frenzy that misled consumers and compromised public health.
BOSTON, March, 25, 2014 /PRNewswire/ — Three professional medical societies and a highly distinguished international group of over 130 scientists and concerned physicians have petitioned the Journal of the American Medical Association to retract the article that precipitated recent concerns regarding cardiovascular risks with testosterone therapy. In a letter addressed to the editor-in-chief of JAMA, Dr. Howard Bauchner, the group cites “gross data mismanagement,” rendering the article “no longer credible.” The article by Rebecca Vigen and colleagues was published in the November 13, 2013 issue of JAMA, entitled “Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels.” The results of this article were widely reported as new evidence that testosterone therapy is associated with cardiovascular risks, resulting in a Food and Drug Administration safety bulletin issued January 31, 2014. The retraction letter was written by the Androgen Study Group.
Hormone Therapeutics April 29th, 2014
Tags: cardiovascular risk, data mismanagement, errors, health risk, journal of american medical association, low t, low testosterone, medical article error, medical literature, mistakes, myocardial infarction, public health, quality of life, retract article, risks associated with testosterone therapy, safety, stroke, testosterone therapy, well-being
The following letter was signed by three medical societies and more than 125 scientists and physicians from 24 countries, including 59 full professors (8 emeritus), 6 journal editors, and 12 medical society presidents. Signers include U.S. faculty from Harvard, Johns Hopkins, Brown, Cornell, Cleveland Clinic, Mayo Clinic, Baylor Medical College, Tufts, and Boston University, among others. The professional societies are The International Society for Sexual Medicine (ISSM), The Sexual Medicine Society of North America (SMSNA), and The International Society for the Study of the Aging Male.
The full letter can be read below or on their website.
Hormone Therapeutics April 29th, 2014
Tags: cardiovascular risk, data mismanagement, errors, health risk, JAMA, journal of american medical association, low t, low testosterone, medical literature, medical mistake, myocardial infarction, public health, quality of life, retract article, risks associated with testosterone therapy, safety, stroke, testosterone therapy, well-being